New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
AIM ImmunoTech Inc. (AIM) vs Niki BioSolutions, Inc. (NIKI)
- AIM ImmunoTech Inc. AIM 0.12 −7.69%
- Niki BioSolutions, Inc. NIKI 1.68 +5.00%
AIM ImmunoTech Inc. and Niki BioSolutions, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Niki BioSolutions, Inc. are of similar size ($5.0M and $4.8M). Niki BioSolutions, Inc. grew revenue faster over the last twelve months: 42.6% against −18.8%. Niki BioSolutions, Inc. has the higher net margin (−921.7% vs −15,526.4%) and the higher return on invested capital (0.00% vs −5,687.5%). Across the 16 metrics below, Niki BioSolutions, Inc. leads on 12 and AIM ImmunoTech Inc. on 4.
Valuation
Profitability
| Metric | AIM | NIKI | Biotechnology median |
|---|---|---|---|
| Gross margin | 38.46% | (87.96%) | 70.18% |
| Operating margin | (12,800.00%) | 0.00% | 0.00% |
| Net margin | (15,526.37%) | (921.74%) | 0.00% |
| Free cash flow margin | (13,792.31%) | 0.00% | 0.00% |
| Return on equity | (2,828.63%) | 0.00% | (51.58%) |
| Return on assets | (185.36%) | 0.00% | (45.91%) |
| Return on invested capital | (5,687.50%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack